<DOC>
	<DOCNO>NCT02840058</DOCNO>
	<brief_summary>Recent scientific advance show important role immune system cancer . Today , many immunological biotherapy like anti-PD1/PDL-1 available cancer treatment generate durable clinical response patient . The development tool monitor anti-tumor immune response dynamically major challenge predict effectiveness immunotherapy anti-PD-1 anti-PDL-1 . Thus , objective study analyse interest monitoring anti-telomerase T helper 1 ( TH1 ) responses predict efficacy immunotherapy , use immunoassay develop group .</brief_summary>
	<brief_title>Interest Anti-telomerase T CD4 Immune Responses Predicting Effectiveness Immunotherapies Targeting PD1 / PDL1</brief_title>
	<detailed_description />
	<criteria>Patient metastatic locally advanced cancer candidate antiPD1/PDL1 immunotherapy Performance status 0 , 1 2 ECOG scale Written inform consent Patients chronic treatment systemic corticoid immunosuppressive drug ( prednisone prednisolone â‰¤ 10 mg/day allow ) Prior history malignancy except : basal cell carcinoma skin , cervical intraepithelial neoplasia cancer curatively treat evidence disease least 5 year Active autoimmune disease , HIV , hepatitis C B virus Patients medical psychiatric condition disease , Patients guardianship , curatorship protection justice .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>